Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (11-20 of 539) with videos related to

Pageof 54
Sort By:
Deutsche Medizinische Wochenschrift (1946)|June 20, 2020
[Current Recommendations for the First-Line Therapy of Symptomatic Multiple Myeloma]Lukas John, Hartmut Goldschmidt, Christof Scheid
Onkologie|April 15, 2010
The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomideStefan Schmitt, Anthony D Ho, Hartmut Goldschmidt
Molecules (Basel, Switzerland)|January 8, 2020
Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple MyelomaChristos Sachpekidis, Hartmut Goldschmidt, Antonia Dimitrakopoulou-Strauss
Therapeutische Umschau. Revue Therapeutique|November 3, 2011
[Immunostimulating drugs and cytokines]Nicola Lehners, Hartmut Goldschmidt, Marc S Raab
Innere Medizin (Heidelberg, Germany)|December 8, 2022
[Teclistamab for the treatment of multiple myeloma]Lilli Sophie Sester, Hartmut Goldschmidt, Sirka Nitschmann
Der Radiologe|December 18, 2021
[Positron emission tomography/computed tomography (PET/CT) in multiple myeloma]Christos Sachpekidis, Hartmut Goldschmidt, Antonia Dimitrakopoulou-Strauss
Annals of Hematology|November 25, 2018
Navigating the treatment landscape in multiple myeloma: which combinations to use and when?Hartmut Goldschmidt, John Ashcroft, Zsolt Szabo, et al.
Srpski Arhiv Za Celokupno Lekarstvo|February 23, 2012
Timing of the high-dose therapy in the area of new drugsStefan Schmitt, Uta Bertsch, Dirk Hose, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 21, 2020
Response Improvement Rather than Response Status after First Autologous Stem Cell Transplantation Is a Significant Prognostic Factor for Survival Benefit from Tandem Compared with Single Transplantation in Multiple Myeloma PatientsJoanna Blocka, Thomas Hielscher, Hartmut Goldschmidt, et al.
Journal of Cancer Research and Clinical Oncology|June 28, 2017
Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myelomaMaximilian Merz, Marc S Raab, Hartmut Goldschmidt, et al.
Pageof 54

Showing results (11-20 of 539) with videos related to

Sort By:
Pageof 54
Deutsche Medizinische Wochenschrift (1946)|June 20, 2020
[Current Recommendations for the First-Line Therapy of Symptomatic Multiple Myeloma]Lukas John, Hartmut Goldschmidt, Christof Scheid
Onkologie|April 15, 2010
The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomideStefan Schmitt, Anthony D Ho, Hartmut Goldschmidt
Molecules (Basel, Switzerland)|January 8, 2020
Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple MyelomaChristos Sachpekidis, Hartmut Goldschmidt, Antonia Dimitrakopoulou-Strauss
Therapeutische Umschau. Revue Therapeutique|November 3, 2011
[Immunostimulating drugs and cytokines]Nicola Lehners, Hartmut Goldschmidt, Marc S Raab
Innere Medizin (Heidelberg, Germany)|December 8, 2022
[Teclistamab for the treatment of multiple myeloma]Lilli Sophie Sester, Hartmut Goldschmidt, Sirka Nitschmann
Der Radiologe|December 18, 2021
[Positron emission tomography/computed tomography (PET/CT) in multiple myeloma]Christos Sachpekidis, Hartmut Goldschmidt, Antonia Dimitrakopoulou-Strauss
Annals of Hematology|November 25, 2018
Navigating the treatment landscape in multiple myeloma: which combinations to use and when?Hartmut Goldschmidt, John Ashcroft, Zsolt Szabo, et al.
Srpski Arhiv Za Celokupno Lekarstvo|February 23, 2012
Timing of the high-dose therapy in the area of new drugsStefan Schmitt, Uta Bertsch, Dirk Hose, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 21, 2020
Response Improvement Rather than Response Status after First Autologous Stem Cell Transplantation Is a Significant Prognostic Factor for Survival Benefit from Tandem Compared with Single Transplantation in Multiple Myeloma PatientsJoanna Blocka, Thomas Hielscher, Hartmut Goldschmidt, et al.
Journal of Cancer Research and Clinical Oncology|June 28, 2017
Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myelomaMaximilian Merz, Marc S Raab, Hartmut Goldschmidt, et al.
Pageof 54